Astellas Pharma Inc is a pharmaceutical company that helps patients through overall medical care including diagnostic, preventive, therapeutic, and prognostic care. The company’s major products are XTANDI (enzalutamide), a treatment for prostate cancer; XOSPATA (gilteritinib), a treatment for patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation; PADCEV (enfortumab vedotin) for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received other treatments; Evrenzo (roxadustat) that deals with anaemia associated with chronic kidney disease (CKD), Betanis/Myrabetriq/BETMIGA (mirabegron) for the treatment of overactive bladder (OAB), and Prograf and Advagraf/Graceptor/ASTAGRAF XL (tacrolimus), which are immunosuppressants. The company’s capability in bioinformatics contributes to diverse fields beyond conventional bioinformatics such as digital biomarker development from image data, optimisation of research by using image or sensor data, contribution to research strategy planning by analysing other company activity, scientific literature, and patent information.